Practical applications of measuring and monitoring MRD in patients with CLL.
O'Brien
Susan
S
Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, USA.
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications* / Q000175:diagnosis* / Q000188:drug therapy; D018365:Neoplasm, Residual / Q000150:complications* / Q000175:diagnosis* / Q000188:drug therapy; D015996:Survival Rate; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000074323:Alemtuzumab